Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5141]

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin...

Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non...

Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )

Advances in lung cancer and current situation in Romania

Dr Serban Negru - University of Medicine and Pharmacy Victor Babes Timisoara...

Advances in lung cancer and current situation in Romania ( Dr Serban Negru - University of Medicine and Pharmacy Victor Babes Timisoara, OncoHelp Cancer Center )

First results of a head-to-head trial of acalabrutinib versus ibrutinib in...

Dr John Byrd - The Ohio State University, Columbus, USA

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University, Columbus, USA )

Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic...

Prof Nicholas Short - The University of Texas MD Anderson Cancer Center...

Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )

EHA 2021: Latest in immunotherapy for R/R multiple myeloma

Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele...

EHA 2021: Latest in immunotherapy for R/R multiple myeloma ( Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cavo )

A comparison of clinical outcomes from ZUMA-5 and the international scholar-5...

Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA

A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control cohort in R/R FL ( Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA )

Clinically sufficient vitamin D levels at breast cancer diagnosis and survival...

Prof Song Yao - Roswell Park Comprehensive Cancer Center, Buffalo, USA

Clinically sufficient vitamin D levels at breast cancer diagnosis and survival outcomes ( Prof Song Yao - Roswell Park Comprehensive Cancer Center, Buffalo, USA )

AL3818 hydrochloride monotherapy in subjects with metastatic or advanced...

Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA

AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma ( Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA )

Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial...

Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA

Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma ( Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA )

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax...

Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health...

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, New Jersey, USA )

CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA...

Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy

CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecular selection in mCC ( Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy )

More from ecancer